Gupta Aditya K, Cherman Andrea M, Tyring Stephen K
Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center, University of Toronto, Toronto, Ontario, Canada.
J Cutan Med Surg. 2004 Sep-Oct;8(5):338-52. doi: 10.1007/s10227-005-0023-5.
Imiquimod is a topical immunomodulator that is indicated for the treatment of external genital and perianal warts. This drug has been recently approved for the treatment of actinic keratoses and superficial basal cell carcinoma. There is a growing body of evidence for its effectiveness in treating a variety of other skin conditions.
This review examines the role of imiquimod 5% cream in the treatment of skin diseases such as actinic keratoses, basal cell carcinoma, Bowen's disease, lentigo maligna, and extramammary Paget's disease.
Published literature containing the words "Imiquimod" or "Aldara" was reviewed and summarized.
This agent has demonstrated indirect antiviral and antitumor effects in animal models. Although the exact mechanism of action is unknown, imiquimod is an agonist for toll-like receptor (TLR) 7 and is thought to act by inducing cytokines, such as interferon alpha (IFN-alpha), interleukin-12 (IL-12), and tumor necrosis factor alpha (TNF-alpha). These cytokines trigger the immune system to recognize the presence of a viral infection or tumor and the associated lesion is ultimately eradicated. Side effects are generally well tolerated with local skin reactions reported most frequently.
Imiquimod has been shown to be a safe and effective treatment for a variety of skin conditions.
咪喹莫特是一种局部免疫调节剂,适用于治疗外生殖器和肛周疣。该药物最近已被批准用于治疗光化性角化病和浅表基底细胞癌。越来越多的证据表明其在治疗多种其他皮肤疾病方面有效。
本综述探讨5%咪喹莫特乳膏在治疗光化性角化病、基底细胞癌、鲍恩病、恶性雀斑样痣和乳房外佩吉特病等皮肤疾病中的作用。
对包含“咪喹莫特”或“艾拉”字样的已发表文献进行综述和总结。
该药物在动物模型中已显示出间接抗病毒和抗肿瘤作用。尽管确切的作用机制尚不清楚,但咪喹莫特是Toll样受体(TLR)7的激动剂,被认为通过诱导细胞因子起作用,如干扰素α(IFN-α)、白细胞介素-12(IL-12)和肿瘤坏死因子α(TNF-α)。这些细胞因子触发免疫系统识别病毒感染或肿瘤的存在,相关病变最终被根除。副作用通常耐受性良好,最常见的是局部皮肤反应。
咪喹莫特已被证明是治疗多种皮肤疾病的安全有效药物。